Cancer is one of the main public healthcare problems on a global scale. In recent years, progress has been made in the prevention and treatment of early-stage cancer. However, very little progress has been made in the development of new methods to fight late and invasive cancer stages.
A group of Spanish, British, and French entrepreneurs, with extensive experience in the biotechnology industry, founded Oncomatrix in 2010, in order to tackle this problem by developing innovative personalised treatments against invasive cancer stages.
Oncomatrix is developing innovative treatments that target the tumourís connection to the surrounding stroma: a cancer treatment aimed at attacking not tumour cells, but the peritumoural cells and extracellular matrix that facilitate tumour invasiveness and resistance.
biological treatments, based on human proteins, human monoclonal antibodies, immunotoxins and drug-antibody conjugates, which specifically target the stroma surrounding the tumour cells. This specificity is crucial to decrease the secondary effects of treatment, and to increase the probability of success of the clinical trials for the treatment, thus decreasing their cost and time length.
They are personalised treatments, accompanied by diagnostic methods and products, which Oncomatrix develops to diagnose the disease and identify patients who express the therapeutic target anomalously and who will be the only ones to receive that treatment from the clinical trials stage. This personalisation will be crucial to increase treatment efficacy and the probability of success of the clinical trials.
They are treatments against invasive cancer stages, for which there are currently no effective therapies, setting the most painful unfinished challenge in Oncology.